blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4355770

EP4355770 - DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  22.03.2024
Database last updated on 19.10.2024
FormerThe international publication has been made
Status updated on  23.12.2022
Formerunknown
Status updated on  29.07.2022
Most recent event   Tooltip16.10.2024New entry: Decision on request for further processing 
Applicant(s)For all designated states
Alexion Pharmaceuticals, Inc.
121 Seaport Boulevard
Boston, MA 02210 / US
[2024/17]
Inventor(s)01 / GAULT, Laura Marie
Boston, Massachusetts 02210 / US
02 / KIELHORN, Adrian Markus
Boston, Massachusetts 02210 / US
03 / RAKHADE, Sanjay Nandkumar
Boston, Massachusetts 02210 / US
04 / SOHUR, Usharbudh Shivraj
Milton, Massachusetts 02186 / US
 [2024/17]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2024/17]
Application number, filing date22741888.609.06.2022
[2024/17]
WO2022US32885
Priority number, dateUS202163210280P14.06.2021         Original published format: US 202163210280 P
[2024/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022265915
Date:22.12.2022
Language:EN
[2022/51]
Type: A1 Application with search report 
No.:EP4355770
Date:24.04.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 22.12.2022 takes the place of the publication of the European patent application.
[2024/17]
Search report(s)International search report - published on:EP22.12.2022
ClassificationIPC:C07K16/18, A61P17/00, A61P21/00, A61P29/00, A61K39/00
[2024/17]
CPC:
C07K16/18 (EP,KR,US); A61K39/395 (EP); A61P17/00 (EP,KR,US);
A61P21/00 (EP,KR,US); A61P29/00 (EP); C07K16/283 (KR,US);
A61K2039/505 (KR,US); A61K2039/545 (EP,US); C07K2317/24 (EP);
C07K2317/76 (EP,KR); C07K2317/92 (KR); C07K2317/94 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/17]
TitleGerman:DOSIERUNG UND VERABREICHUNG VON ANTI-C5-ANTIKÖRPERN ZUR BEHANDLUNG VON DERMATOMYOSITIS (DM)[2024/17]
English:DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM)[2024/17]
French:DOSAGE ET ADMINISTRATION D'ANTICORPS ANTI-C5 POUR LE TRAITEMENT DE LA DERMATOMYOSITE (DM)[2024/17]
Entry into regional phase08.12.2023National basic fee paid 
08.12.2023Designation fee(s) paid 
08.12.2023Examination fee paid 
Examination procedure08.12.2023Examination requested  [2024/17]
08.12.2023Date on which the examining division has become responsible
13.08.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
11.10.2024Amendment by applicant (claims and/or description)
Request for further processing for:11.10.2024Request for further processing filed
11.10.2024Full payment received (date of receipt of payment)
Request granted
15.10.2024Decision despatched
Fees paidRenewal fee
27.06.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[IY]US2020254092  (PAYTON LORI [US], et al) [I] 1-57,61 * See e.g. SEQ ID NOs: 3-6, 8,12, 13, 18 and 19; paragraphs 71 and 206; abstract * [Y] 1-57,61;
 [IY]US2021091937  (DANGE AMOD ASHOK [US], et al) [I] 1-57,61 * See e.g. SEQ ID NOs: 3-6, 8, 12, 13, 18 and 19; abstract; claim 21; page 14, last line; page 29, lines 10-18 * [Y] 1-57,61;
 [IY]  - FEDERICA VANONI ET AL, "A difficult case of juvenile dermatomyositis complicated by thrombotic microangiopathy and purtscher-like retinopathy", PEDIATRIC RHEUMATOLOGY, BIOMED CENTRAL LTD, LO, (20140917), vol. 12, no. Suppl 1, doi:10.1186/1546-0096-12-S1-P275, ISSN 1546-0096, page P275, XP021197667 [I] 1-57,61 * See e.g. page 275, right column, third paragraph * [Y] 1-57,61

DOI:   http://dx.doi.org/10.1186/1546-0096-12-S1-P275
 [IY]  - GORDON PATRICK A ET AL, "Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, US, doi:10.1002/14651858.CD003643.pub4, ISSN 1465-1858, (20120815), URL: http://dx.doi.org/10.1002/14651858.CD003643.pub4, XP055958762 [I] 1-57,61 * See e.g. page 275, right column, second paragraph * [Y] 1-57,61

DOI:   http://dx.doi.org/10.1002/14651858.CD003643.pub4
 [Y]  - PATRIQUIN CHRISTOPHER J ET AL, "Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics", TRANSFUSION MEDICINE REVIEWS, GRUNE AND STRATTON, ORLANDO, FL, US, vol. 33, no. 4, doi:10.1016/J.TMRV.2019.09.004, ISSN 0887-7963, (20191001), pages 256 - 265, (20191022), XP085953817 [Y] 1-57,61 * See e.g. page 257, right column, 3rd paragraph; page 258, right column, 1st paragraph *

DOI:   http://dx.doi.org/10.1016/j.tmrv.2019.09.004
 [IP]  - MCCOMBE JENNIFER A ET AL, "Anti-complement Agents for Autoimmune Neurological Disease", NEUROTHERAPEUTICS, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 19, no. 3, doi:10.1007/S13311-022-01223-W, ISSN 1933-7213, (20220401), pages 711 - 728, (20220512), XP037905801 [IP] 1-57,61 * See e.g. page 718; page 723, left column, 3rd paragraph *

DOI:   http://dx.doi.org/10.1007/s13311-022-01223-w
by applicantUS8241628
 US8883158
 US9079949
 WO2015134894
 US9765135
 US10633434
    - DALAKAS MC., N. Engl. J. Med., (20150000), vol. 372, no. 18, pages 1734 - 1747
    - ISAK V. et al., J. Dermatolog. Treat., (20180000), vol. 29, no. 5, pages 450 - 459
    - MAHIL S. et al., Br. J. Hosp. Med. (Lond)., (20120000), vol. 73, no. 2, pages C18 - 22
    - SELVA-O'CALLAGHAN A et al., The Lancet Neurology, (20180000), vol. 17, no. 9, pages 816 - 828
    - DALAKAS MC et al., Nat. Rev. Neurol., (20200000), vol. 16, no. 11, pages 601 - 617
    - KISSEL JT et al., N. Engl. J. Med., (19860000), vol. 314, no. 6, pages 329 - 334
    - DALAKAS MC et al., Lancet, (20030000), vol. 362, no. 9388, pages 971 - 982
    - MARIE I et al., J. Rheumatol., (20010000), vol. 28, no. 10, pages 2230 - 2237
    - BENDEWALD MJ et al., Archives of dermatology, (20100000), vol. 146, no. 1, pages 26 - 30
    - BOHAN APETER JB., N. Engl. J. Med., (19750000), vol. 292, no. 7, pages 344 - 347
    - MAHIL S et al., Br. J. Hosp. Med. (Lond, (20120000), vol. 73, no. 2, pages C12 - 22
    - ERNSTE FC et al., Mayo. Clin. Proc., (20130000), vol. 88, no. 1, pages 83 - 105
    - ISAK V et al., J. Dermatolog Treat., (20180000), vol. 29, no. 5, pages 450 - 459
    - CHANDRA T et al., Expert Opin. Emerg. Drugs., (20200000), pages 1 - 16
    - MARIE I et al., JRheumatol, (20010000), vol. 28, no. 10, pages 2230 - 2237
    - RIDER LG et al., JAMA, (20110000), vol. 305, no. 2, pages 183 - 190
    - MAHIL S et al., Br. J. Hosp. Med., (20120000), vol. 73, no. 2, pages c18 - 22
    - MAGRO CM et al., J. Cutan. Pathol., (19970000), vol. 24, no. 9, pages 543 - 552
    - PINAL-FERNANDEZ I et al., J Rheumatol, (20150000), vol. 42, no. 8, pages 1448 - 1454
    - HARRIS CL et al., Mol. Immunol., (20180000), vol. 102, pages 89 - 119
    - SALLUM AM et al., Autoimmun. Rev., (20060000), vol. 5, no. 2, pages 93 - 100
    - TEGLA CA et al., Immunol. Res., (20110000), vol. 51, no. 1, pages 45 - 60
    - DALAKAS MC et al., Lancet., (20030000), vol. 362, no. 9388, pages 971 - 982
    - SUAREZ-CALVET X et al., Arthritis. Res. Ther., (20170000), vol. 19, no. 1, page 174
    - FUKUZAWA, T et al., Sci. Rep., (20170000), vol. 7, page 1080
    - JONSSON, U. et al., Biotechniques, (19910000), vol. 11, pages 620 - 7
    - CHOTHIA et al., Nature, (19890000), vol. 342, pages 877 - 83
    - THOMAS, C. et al., Mol. Immunol., (19960000), vol. 33, pages 1389 - 401
    - DALL'ACQUA, W. et al., J. Biol. Chem., (20060000), vol. 281, pages 23514 - 24
    - HINTON, P. et al., J. Biol. Chem., (20040000), vol. 279, pages 6213 - 6
    - HINTON, P. et al., J. Immunol., (20060000), vol. 176, pages 346 - 56
    - PETKOVA, S. et al., Int. Immunol., (20060000), vol. 18, pages 1759 - 69
    - DATTA-MANNAN, A. et al., J. Biol. Chem., (20070000), vol. 282, pages 1709 - 17
    - HILLMEN, P. et al., N. Engl. J. Med., (20040000), vol. 350, pages 552 - 9
    - JOHNE, B. et al., J. Immunol. Meth., (19930000), vol. 160, pages 191 - 8
    - JONSSON, U. et al., Ann. Biol. Clin., (19930000), vol. 51, pages 19 - 26
    - CC THOMAS, Experimental Immunochemistry, Springfield, (19610000), pages 135 - 139
    - EVANS, M. et al., Mol. Immunol., (19950000), vol. 32, pages 1183 - 95
    - KOHLER, G.MILSTEIN, C., Eur. J. Immunol., (19760000), vol. 6, pages 511 - 9
    - HUSE, W. et al., Science, (19890000), vol. 246, pages 1275 - 81
    - SCHRAG A et al., Journal of neurology, neurosurgery, and psychiatry, (20000000), vol. 69, no. 1, pages 67 - 73
    - LUNDBERG IE et al., Arthritis Rheumatol, (20170000), vol. 69, no. 12, pages 2271 - 2282
    - "Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity", RIDER LG et al., Manual Muscle Testing (MMT
    - RIDER LG et al., "63", Arthritis Care Res (Hoboken, (20110000), vol. 63, pages S1 18 - 157
    - AGGARWAL R et al., "American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis", Arthritis Rheumatol, (20160000), vol. 69, no. 5, pages 898 - 910
    - RIDER LG et al., Arthritis Care Res (Hoboken, (20110000), vol. 63, pages 118 - 157
    - ELMAN et al., Br. J. Dermatol, (20100300), vol. 162, no. 3, pages 587 - 93
    - HAYS et al., Qual. Life Res., (20180700), vol. 27, no. 7, pages 1885 - 1891
    - STEWART AL et al., Med Care, (19880000), vol. 26, no. 7, pages 724 - 735
    - WARE et al., Med Care, (19920000), vol. 30, no. 6, pages 473 - 483
    - TENNANT, K., Supportive Care in Cancer 23.5, (20150000), pages 1355 - 1364
    - AGARWAL SKIELY PD, Rheumatology (Oxford, (20060000), vol. 45, no. 7, pages 874 - 879
    - RIDER LG et al., Nat. Rev. Rheumatol., (20180000), vol. 14, no. 5, pages 303 - 318
    - MANTEL NHAENSZEL W., J. Natl. Cancer Inst., (19590000), vol. 22, no. 4, pages 719 - 748
    - Biometrics, (19890000), vol. 45, pages 1323 - 1324
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.